AstraZeneca and Pfizer CEOs express commitment to expanding the biopharmaceutical industry in China despite US-China tensions. AstraZeneca plans to launch 100 new medicines in China in the next five years and establish independent drug supply chains for the US and China.
WuXi Biologics stays the course with positive 2024 outlook as national security crackdown threatens business in US https://t.co/6XQZVKyRdO
AstraZeneca plans independent drug supply chains for US and China, CEO says https://t.co/MMRZjLMos0
AstraZeneca CEO Soriot on Pharmaceuticals in China https://t.co/3VW5bEdR0s
AstraZeneca is fleshing out plans for a global manufacturing network that will independently supply medicine to major markets as the US pushes to reduce the pharmaceutical industry’s reliance on China https://t.co/BMugKwnIjT
Big Pharma CEOs gather in Beijing to show continued interest in China, offer policy advice https://t.co/IRgnxkuH6G
Astra, Pfizer Boost China Bets Despite US Drive to Decouple Bourla: “I’m encouraged by opportunities to continue to expand the biopharmaceutical industry in China. I’m particularly inspired by the prospect of holistic, innovative drug development here.” https://t.co/L5p9i4yNiz
The chief executive officers of AstraZeneca and Pfizer pledge to support expansion of China’s biopharmaceutical industry, even as US politicians seek to decouple the tightly entwined supply chains that provide medicine to the world https://t.co/lSeVmaZ1Gj
BEIJING-ASTRAZENECA CEO: EXPECT TO LAUNCH ABOUT 100 NEW MEDICINES AND INDICATIONS IN CHINA IN NEXT FIVE YEARS